PMC:7781431 / 9747-9951 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"286","span":{"begin":41,"end":53},"obj":"Disease"}],"attributes":[{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"MESH:D007249"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"and RvD5 peak at the early stages of the inflammation termination phase (6–24 hours) (Dalli et al. 2013b). RvD3 appears to be produced by a subpopulation of macrophages with high 15-LOX activity (Dalli et"}

{"project":"LitCovid-sentences","denotations":[{"id":"T80","span":{"begin":99,"end":106},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"and RvD5 peak at the early stages of the inflammation termination phase (6–24 hours) (Dalli et al. 2013b). RvD3 appears to be produced by a subpopulation of macrophages with high 15-LOX activity (Dalli et"}